A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Mohamed, Mohamed F ^a   Brezden, Anna ^b   Mohammad, Haroon ^a   Chmielewski, Jean ^b   Seleem, Mohamed N ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; COLISTIN;

ACINETOBACTER BAUMANNII; ANIMAL; BIOFILM; CAENORHABDITIS ELEGANS; CHEMISTRY; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFECT; DRUG STABILITY; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SYNTHESIS;

ACINETOBACTER BAUMANNII; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CAENORHABDITIS ELEGANS; COLISTIN; CYSTIC FIBROSIS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG STABILITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85026639061     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07440-0     Document Type: Article

References (54)

1. Doi, Y., Murray, G. L., Peleg, A. Y. Acinetobacter baumannii: Evolution of Antimicrobial Resistance-Treatment Options. Seminars in respiratory and critical care medicine 36, 85-98, doi: 10.1055/s-0034-1398388 (2015).
2. Viale, P., Giannella, M., Tedeschi, S., Lewis, R. Treatment of MDR-Gram negative infections in the 21st century: A never ending threat for clinicians. Curr Opin Pharmacol 24, 30-37, doi: 10.1016/j.coph.2015.07.001 (2015).
3. Breidenstein, E. B., de la Fuente-Nunez, C., Hancock, R. E. Pseudomonas aeruginosa: All roads lead to resistance. Trends in microbiology 19, 419-426, doi: 10.1016/j.tim.2011.04.005 (2011).
4. Turner, J., Cho, Y., Dinh, N. N., Waring, A. J., Lehrer, R. I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrobial agents and chemotherapy 42, 2206-2214 (1998).
5. Chu, H. L. et al. Boosting salt resistance of short antimicrobial peptides. Antimicrobial agents and chemotherapy 57, 4050-4052, doi: 10.1128/AAC.00252-13 (2013).
6. Goldman, M. J. et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88, 553-560 (1997).
7. Mohamed, M. F., Hamed, M. I., Panitch, A., Seleem, M. N. Targeting Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic Peptides. Antimicrobial agents and chemotherapy 58, 4113-4122, doi: 10.1128/AAC.02578-14 (2014).
8. Mohamed, M. F., Seleem, M. N. Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug design, development and therapy 8, 1979-1983, doi: 10.2147/DDDT.S72129 (2014).
9. Blondelle, S. E., Houghten, R. A. Design of model amphipathic peptides having potent antimicrobial activities. Biochemistry 31, 12688-12694 (1992).
10. Hawrani, A., Howe, R. A., Walsh, T. R., Dempsey, C. E. Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. The Journal of biological chemistry 283, 18636-18645, doi: 10.1074/jbc.M709154200 (2008).
11. Deslouches, B. et al. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrobial agents and chemotherapy 57, 2511-2521, doi: 10.1128/AAC.02218-12 (2013).
12. Deslouches, B. et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: Implications for systemic applications. Antimicrobial agents and chemotherapy 49, 3208-3216, doi: 10.1128/aac.49.8.3208-3216.2005 (2005).
13. Chan, D. I., Prenner, E. J., Vogel, H. J. Tryptophan-A nd arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochimica et biophysica acta 1758, 1184-1202, doi: 10.1016/j.bbamem.2006.04.006 (2006).
14. Ong, Z. Y. et al. Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic beta-sheet forming peptide amphiphiles. Biomaterials 35, 1315-1325, doi: 10.1016/j.biomaterials.2013.10.053 (2014).
15. Ong, Z. Y., Wiradharma, N., Yang, Y. Y. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials. Advanced drug delivery reviews 78, 28-45, doi: 10.1016/j.addr.2014.10.013 (2014).
16. Hancock, R. E., Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature biotechnology 24, 1551-1557, doi: 10.1038/nbt1267 (2006).
17. Wade, D. et al. All-D Amino Acid-Containing Channel-Forming Antibiotic Peptides. Proceedings of the National Academy of Sciences of the United States of America 87, 4761-4765, doi: 10.1073/pnas.87.12.4761 (1990).
18. de la Fuente-Nunez, C. et al. D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol 22, 196-205, doi: 10.1016/j.chembiol.2015.01.002 (2015).
19. Bonchi, C., Frangipani, E., Imperi, F., Visca, P. Pyoverdine and Proteases Affect the Response of Pseudomonas aeruginosa to Gallium in Human Serum. Antimicrobial agents and chemotherapy 59, 5641-5646, doi: 10.1128/AAC.01097-15 (2015).
20. Antunes, L. C., Imperi, F., Minandri, F., Visca, P. In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy 56, 5961-5970, doi: 10.1128/aac.01519-12 (2012).
21. Antunes, L. C., Imperi, F., Carattoli, A., Visca, P. Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity. PloS one 6, e22674, doi: 10.1371/journal.pone.0022674 (2011).
22. Steadman, R., Heck, L. W., Abrahamson, D. R. In Pseudomonas aeruginosa as an Opportunistic Pathogen (eds Mario Campa, Mauro Bendinelli, & Herman Friedman) 129-143 (Springer US, 1993).
23. Moskowitz, S. M. et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrobial agents and chemotherapy 56, 1019-1030, doi: 10.1128/AAC.05829-11 (2012).
24. Abou Alaiwa, M. H. et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials beta-defensin-3 and LL-37. Proceedings of the National Academy of Sciences of the United States of America 111, 18703-18708, doi: 10.1073/pnas.1422091112 (2014).
25. Shah, V. S. et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science 351, 503-507, doi: 10.1126/science.aad5589 (2016).
26. Yeung, A. T., Gellatly, S. L., Hancock, R. E. Multifunctional cationic host defence peptides and their clinical applications. Cellular and molecular life sciences: CMLS 68, 2161-2176, doi: 10.1007/s00018-011-0710-x (2011).
27. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395, doi: 10.1038/415389a (2002).
28. Hoffman, L. R. et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436, 1171-1175, doi: 10.1038/nature03912 (2005).
29. Alder, J., Eisenstein, B. The Advantage of Bactericidal Drugs in the Treatment of Infection. Curr Infect Dis Rep 6, 251-253 (2004).
30. Hurdle, J. G., O'Neill, A. J., Chopra, I., Lee, R. E. Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections. Nature reviews. Microbiology 9, 62-75, doi: 10.1038/nrmicro2474 (2011).
31. Buyck, J. M., Tulkens, P. M., Van Bambeke, F. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrobial agents and chemotherapy 57, 2310-2318, doi: 10.1128/AAC.02609-12 (2013).
32. Garcia-Medina, R., Dunne, W. M., Singh, P. K., Brody, S. L. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infection and immunity 73, 8298-8305, doi: 10.1128/IAI.73.12.8298-8305.2005 (2005).
33. Qiu, H. et al. Role of Macrophages in Early Host Resistance to Respiratory Acinetobacter baumannii/Infection. PloS one 7, e40019, doi: 10.1371/journal.pone.0040019 (2012).
34. Cappiello, F. et al. Esculentin-1a-Derived Peptides Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a Plausible Mode of Action. Antimicrobial agents and chemotherapy 60, 7252-7262, doi: 10.1128/AAC.00904-16 (2016).
35. Uccelletti, D. et al. Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: A plausible mode of action in vitro and in vivo. Antimicrobial agents and chemotherapy 54, 3853-3860, doi: 10.1128/AAC.00154-10 (2010).
36. Jayamani, E. et al. Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrobial agents and chemotherapy 59, 1728-1737, doi: 10.1128/AAC.04198-14 (2015).
37. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. CLSI, Wayne, PA (2007).
38. Kuriakose, J. et al. Targeting intracellular pathogenic bacteria with unnatural proline-rich peptides: Coupling antibacterial activity with macrophage penetration. Angew Chem Int Ed Engl 52, 9664-9667, doi: 10.1002/anie.201302693 (2013).
39. Mohamed, M. F., Hammac, G. K., Guptill, L., Seleem, M. N. Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant Staphylococcus pseudintermedius from infected dogs. PloS one 9, e116259, doi: 10.1371/journal.pone.0116259 (2014).
40. Bahnsen, J. S., Franzyk, H., Sandberg-Schaal, A., Nielsen, H. M. Antimicrobial and cell-penetrating properties of penetratin analogs: Effect of sequence and secondary structure. Biochimica et biophysica acta 1828, 223-232, doi: 10.1016/j.bbamem.2012.10.010 (2013).
41. O'Toole, G. A. Microtiter dish biofilm formation assay. J Vis Exp. doi: 10.3791/2437 (2011).
42. Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J., Seleem, M. N. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate. Biochimica et Biophysica Acta (BBA)-General Subjects 1861, 848-859, doi: 10.1016/j.bbagen.2017.01.029 (2017).
43. Thangamani, S., Mohammad, H., Abushahba, M. F., Sobreira, T. J., Seleem, M. N. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Int J Antimicrob Agents 47, 195-201, doi: 10.1016/j.ijantimicag.2015.12.016 (2016).
44. Mohamed, M. F., Abdelkhalek, A., Seleem, M. N. Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 6, 29707, doi: 10.1038/srep29707 (2016).
45. Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J., Seleem, M. N. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate. Biochim Biophys Acta 1861, 848-859, doi: 10.1016/j.bbagen.2017.01.029 (2017).
46. Yan, J. et al. Two hits are better than one: Membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin. Antimicrobial agents and chemotherapy 57, 220-228, doi: 10.1128/AAC.01619-12 (2013).
47. Nagant, C. et al. Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments. Antimicrobial agents and chemotherapy 56, 5698-5708, doi: 10.1128/AAC.00918-12 (2012).
48. Brezden, A. et al. Dual Targeting of Intracellular Pathogenic Bacteria with a Cleavable Conjugate of Kanamycin and an Antibacterial Cell-Penetrating Peptide. J Am Chem Soc. doi: 10.1021/jacs.6b04831 (2016).
49. Thangamani, S. et al. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci Rep 6, 22571, doi: 10.1038/srep22571 (2016).
50. Soofi, M. A., Seleem, M. N. Targeting essential genes in Salmonella enterica serovar typhimurium with antisense peptide nucleic acid. Antimicrob Agents Chemother 56, 6407-6409, doi: 10.1128/AAC.01437-12 (2012).
51. Alajlouni, R. A., Seleem, M. N. Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. Nucleic Acid Ther 23, 363-367, doi: 10.1089/nat.2013.0426 (2013).
52. Srivastava, S., Ghosh, J. K. Introduction of a lysine residue promotes aggregation of temporin L in lipopolysaccharides and augmentation of its antiendotoxin property. Antimicrobial agents and chemotherapy 57, 2457-2466, doi: 10.1128/aac.00169-13 (2013).
53. Moy, T. I. et al. Identification of novel antimicrobials using a live-animal infection model. Proceedings of the National Academy of Sciences of the United States of America 103, 10414-10419, doi: 10.1073/pnas.0604055103 (2006).
54. Tampakakis, E., Okoli, I., Mylonakis, E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nature protocols 3, 1925-1931, doi: 10.1038/nprot.2008.193 (2008).